|
Market Closed -
Nasdaq
01:30:00 22/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 438.34 USD | -0.14% |
|
+2.87% | +33.92% |
| 21/10 | Barclays Adjusts Price Target on Amgen to $400 From $380 | MT |
| 21/10 | Positive Results for an AstraZeneca and Amgen Product |  |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,26,718 | 1,40,139 | 1,54,142 | 1,40,103 | 1,76,250 | 2,36,981 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 34.46% | - | - |
| Enterprise Value (EV) 1 | 1,51,990 | 1,69,779 | 2,07,811 | 1,88,229 | 2,21,725 | 2,78,337 | 2,72,284 | 2,67,412 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 25.53% | -2.17% | -1.79% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 27.8x | 24.8x | 23.8x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 21.2x | 17.2x | 13.8x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.6x | 2.1x | 5.53x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 6.08x | 5.87x | 5.67x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 7.14x | 6.75x | 6.4x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 12.8x | 12.2x | 12x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 16.4x | 15.3x | 14.5x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 25x | 18.3x | 17.1x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 3.99% | 5.47% | 5.84% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.3% | 2.43% | 2.54% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.75 | 17.64 | 18.4 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 64.1% | 60.4% | 60.4% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,967 | 40,352 | 41,806 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,765 | 22,232 | 22,226 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,949 | 17,755 | 18,503 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,546 | 9,420 | 9,979 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,357 | 35,304 | 30,432 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 438.34 | 438.34 | 438.34 |
| Nbr of stocks (in thousands) | 5,63,266 | 5,33,579 | 5,35,178 | 5,37,533 | 5,38,481 | 5,40,632 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.83x | 7.14x | 12.79x | 2.3% | 24TCr | |
| 36.67x | 13.07x | 27.74x | 0.54% | 1,13300Cr | |
| 37.73x | 6.36x | 17.89x | 2.07% | 62TCr | |
| 36.35x | 8.36x | 17.26x | 2.41% | 50TCr | |
| 21.21x | 5.12x | 12.74x | 2.55% | 38TCr | |
| 109.25x | 6.09x | 26.14x | 2.27% | 37TCr | |
| 21.57x | 5.62x | 13.82x | 2.84% | 29TCr | |
| 22.08x | 4.46x | 12.77x | 1.98% | 26TCr | |
| -44.76x | 6.88x | 26.67x | 2.15% | 19TCr | |
| 11.45x | 4.2x | 8.56x | 4.39% | 17TCr | |
| Average | 27.94x | 6.73x | 17.64x | 2.35% | 41.62TCr | |
| Weighted average by Cap. | 34.57x | 8.10x | 19.87x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
